| MeSH term | MeSH ID | Detail |
|---|---|---|
| Bacterial Infections | D001424 | 21 associated lipids |
| Pain | D010146 | 64 associated lipids |
| Lupus Erythematosus, Systemic | D008180 | 43 associated lipids |
| Stomach Diseases | D013272 | 7 associated lipids |
| Lung Diseases | D008171 | 37 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Skin Neoplasms | D012878 | 12 associated lipids |
| Colitis | D003092 | 69 associated lipids |
| Leishmaniasis, Visceral | D007898 | 13 associated lipids |
| Diabetes Mellitus, Type 1 | D003922 | 56 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Liu KS et al. | Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial. | 2014 | Gut | pmid:24295850 |
| Miwa S et al. | Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study. | 2014 | Ann Am Thorac Soc | pmid:24298907 |
| Saadat A et al. | The formulation, chemical and physical characterisation of clarithromycin-based macrolide solution pressurised metered dose inhaler. | 2014 | J. Pharm. Pharmacol. | pmid:24329164 |
| Rajput P et al. | Bifunctional capsular dosage form: novel fanicular cylindrical gastroretentive system of clarithromycin and immediate release granules of ranitidine HCl for simultaneous delivery. | 2014 | Int J Pharm | pmid:24309435 |
| Katayama M et al. | Preliminary study of effects of multiple oral dosing of clarithromycin on the pharmacokinetics of cyclosporine in dogs. | 2014 | J. Vet. Med. Sci. | pmid:24189617 |
| Papastergiou V et al. | Current and future insights in H. pylori eradication regimens: the need of tailoring therapy. | 2014 | Curr. Pharm. Des. | pmid:24180408 |
| Tan X and Song Z | Human saliva-based quantitative monitoring of clarithromycin by flow injection chemiluminescence analysis: a pharmacokinetic study. | 2014 | Appl. Biochem. Biotechnol. | pmid:24166104 |
| Kakuda TN et al. | Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies. | 2014 | J. Antimicrob. Chemother. | pmid:24155058 |
| Seung KJ et al. | Salvage therapy for multidrug-resistant tuberculosis. | 2014 | Clin. Microbiol. Infect. | pmid:23991934 |
| Yakoob J et al. | Comparison of antimicrobial activity of zinc chloride and bismuth subsalicylate against clinical isolates of Helicobacter pylori. | 2014 | Microb. Drug Resist. | pmid:23844851 |
| Kathariya R et al. | Evaluation of subgingivally delivered 0.5% clarithromycin as an adjunct to nonsurgical mechanotherapy in the management of chronic periodontitis: a short-term double blinded randomized control trial. | 2014 | J Investig Clin Dent | pmid:23097216 |
| Shahbazi Niaz M et al. | Investigation into physical-chemical variables affecting the manufacture and dissolution of wet-milled clarithromycin nanoparticles. | 2014 | Pharm Dev Technol | pmid:24093825 |
| Maev IV et al. | [Eradication therapy for Helicobacter pylori infection: review of world trends]. | 2014 | Ter. Arkh. | pmid:24779078 |
| Katagiri S et al. | [Case report; Disseminated Mycobacterium abscessus infection with hemophagocytic syndrome during treatment of chronic lymphocytic leukemia]. | 2014 | Nippon Naika Gakkai Zasshi | pmid:24796145 |
| Kato M | [Expanded indication of National Health Insurance for H. pylori associated gastritis]. | 2014 | Nippon Rinsho | pmid:24912302 |
| Bjerre M et al. | Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: the CLARICOR trial. | 2014 | Scand. J. Clin. Lab. Invest. | pmid:25026506 |
| Khoshnood A et al. | Replacement of clarithromycin with azithromycin in triple therapy regimens for the eradication of Helicobacter pylori: A randomized clinical trial. | 2014 | J Med Life | pmid:25408735 |
| Noh TK et al. | Infection with Mycobacterium fortuitum during acupoint embedding therapy. | 2014 | J. Am. Acad. Dermatol. | pmid:24831334 |
| Zhao Y and Hu ZY | Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate. | 2014 | Br. J. Pharmacol. | pmid:24283665 |
| Loreto ES et al. | New insights into the in vitro susceptibility of Pythium insidiosum. | 2014 | Antimicrob. Agents Chemother. | pmid:25223997 |
| Harvey E and Varatharaj A | Round pneumonia. | 2014 | QJM | pmid:23708793 |
| Tsovolou EC et al. | Effect of clarithromycin in experimental empyema by multidrug-resistant Pseudomonas aeruginosa. | 2014 | APMIS | pmid:23656439 |
| Altman E et al. | Lipopolysaccharide glycotyping of clarithromycin-resistant and clarithromycin-susceptible Canadian isolates of Helicobacter pylori. | 2014 | Can. J. Microbiol. | pmid:24392924 |
| Kim SY et al. | Changes in serum immunomolecules during antibiotic therapy for Mycobacterium avium complex lung disease. | 2014 | Clin. Exp. Immunol. | pmid:24354934 |
| De Francesco V et al. | Change of point mutations in Helicobacter pylori rRNA associated with clarithromycin resistance in Italy. | 2014 | J. Med. Microbiol. | pmid:24344205 |
| Yamada K et al. | Azithromycin inhibits MUC5AC induction via multidrug-resistant Acinetobacter baumannii in human airway epithelial cells. | 2014 | Pulm Pharmacol Ther | pmid:24910464 |
| Lee JY et al. | Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. | 2014 | Dig. Dis. Sci. | pmid:24599773 |
| Zhao HM et al. | [Clinical effect of triple therapy combined with Saccharomyces boulardii in the treatment of Helicobacter pylori infection in children]. | 2014 | Zhongguo Dang Dai Er Ke Za Zhi | pmid:24661511 |
| Patsche CB et al. | Disseminated Mycobacterium celatum disease with prolonged pulmonary involvement. | 2014 | Int. J. Infect. Dis. | pmid:25008771 |
| Koh S et al. | Visualization of the meibomian glands by means of noncontact mobile-type meibography (Meibopen) in a 16-year-old girl with unilateral marginal staphylococcal keratitis. | 2014 | J AAPOS | pmid:24568999 |
| Ke AB et al. | Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies. | 2014 | Clin. Pharmacol. Ther. | pmid:24747234 |
| Oğuz M and Mihçiokur H | Environmental risk assessment of selected pharmaceuticals in Turkey. | 2014 | Environ. Toxicol. Pharmacol. | pmid:24929476 |
| Mendu ML and Waikar SS | Drug-drug interactions and acute kidney injury: caveat prescriptor. | 2014 | Am. J. Kidney Dis. | pmid:24820318 |
| Tranos P et al. | Bilateral diffuse iris atrophy after the use of oral clarithromycin. | 2014 | Cutan Ocul Toxicol | pmid:23763291 |
| Page SR and Yee KC | Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin. | 2014 | Intern Med J | pmid:25041770 |
| Noguchi S et al. | Polymorphic transformation of antibiotic clarithromycin under acidic condition. | 2014 | J Pharm Sci | pmid:24375227 |
| Methaneethorn J et al. | A pharmacokinetic drug-drug interaction model of simvastatin and clarithromycin in humans. | 2014 | Conf Proc IEEE Eng Med Biol Soc | pmid:25571290 |
| Phillips RO et al. | Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease. | 2014 | Antimicrob. Agents Chemother. | pmid:24323473 |
| Hajaghamohammadi A et al. | Low dose furazolidone for eradication of H- pylori instead of clarithromycin: a clinical trial. | 2014 | Glob J Health Sci | pmid:25560342 |
| Iwanczak B et al. | Genotypic and clinical differences of seropositive Helicobacter pylori children and adults in the Polish population. | 2014 | J. Physiol. Pharmacol. | pmid:25554984 |
| Rakici H et al. | Comparison of levofloxacin- and moxifloxacin-based triple therapies with standard treatment in eradication of Helicobacter pylori as first-line therapy. | 2014 | Digestion | pmid:25547786 |
| El-Garem Y et al. | Seminal Helicobacter pylori treatment improves sperm motility in infertile asthenozoospermic men. | 2014 | Urology | pmid:25432826 |
| Kim SY et al. | [Ten day concomitant therapy is superior to ten day sequential therapy for Helicobacter pylori eradication]. | 2014 | Korean J Gastroenterol | pmid:25420735 |
| Mustafa G and Necati B | Clarithromycin-associated rhabdomyolysis in an infant. | 2014 | J Clin Rheumatol | pmid:25417692 |
| Hashim H et al. | Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson's disease. | 2014 | PLoS ONE | pmid:25411976 |
| Yangco BG et al. | Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART? | 2014 | AIDS Patient Care STDS | pmid:24833016 |
| Ghrew MH et al. | Successful renal transplant in patient with controlled pulmonary non-tuberculous mycobacterium infection. | 2014 | Libyan J Med | pmid:25249307 |
| Yoon KH et al. | Clarithromycin-based standard triple therapy can still be effective for Helicobacter pylori eradication in some parts of the Korea. | 2014 | J. Korean Med. Sci. | pmid:25246742 |
| Matongo F and Nwodo UU | In vitro assessment of Helicobacter pylori ureases inhibition by honey fractions. | 2014 | Arch. Med. Res. | pmid:25240315 |
| Martos M et al. | Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions. | 2014 | Eur J Gastroenterol Hepatol | pmid:25229983 |
| Veraldi S et al. | Treatment of sporotrichoid fish tank granuloma with pulsed clarithromycin. | 2014 | Dermatology (Basel) | pmid:25228273 |
| Phillips RO et al. | Reply to "compliance with antimicrobial therapy for buruli ulcer". | 2014 | Antimicrob. Agents Chemother. | pmid:25225343 |
| Klis S et al. | Compliance with antimicrobial therapy for buruli ulcer. | 2014 | Antimicrob. Agents Chemother. | pmid:25225342 |
| Mitui M et al. | Novel Helicobacter pylori sequencing test identifies high rate of clarithromycin resistance. | 2014 | J. Pediatr. Gastroenterol. Nutr. | pmid:25222804 |
| Gold BD | Resistance testing for Helicobacter pylori infection: is it finally ready for prime time? | 2014 | J. Pediatr. Gastroenterol. Nutr. | pmid:25222802 |
| Morakul B et al. | Dissolution enhancement and in vitro performance of clarithromycin nanocrystals produced by precipitation-lyophilization-homogenization method. | 2014 | Eur J Pharm Biopharm | pmid:25201298 |
| Peng YC et al. | Clarithromycin modulates Helicobacter pylori-induced activation of nuclear factor-κB through classical and alternative pathways in gastric epithelial cells. | 2014 | Clin. Exp. Med. | pmid:23129507 |
| Park CS et al. | Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance. | 2014 | Am. J. Gastroenterol. | pmid:25091062 |
| Cicek-Senturk G et al. | Acute mercury poisoning presenting as fever of unknown origin in an adult woman: a case report. | 2014 | J Med Case Rep | pmid:25084829 |
| Bilgin M et al. | Acute coronary syndrome secondary to clarithromycin: the first case and review of the literature. | 2014 | Turk Kardiyol Dern Ars | pmid:25080953 |
| Hsu PI et al. | Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection. | 2014 | Antimicrob. Agents Chemother. | pmid:25070099 |
| Patel SK et al. | Helicobacter pylori is not eradicated after triple therapy: a nested PCR based study. | 2014 | Biomed Res Int | pmid:25054141 |
| Elkhatib W and Noreddin A | Efficacy of ciprofloxacin-clarithromycin combination against drug-resistant Pseudomonas aeruginosa mature biofilm using in vitro experimental model. | 2014 | Microb. Drug Resist. | pmid:25050970 |
| Ohe M and Bohgaki T | Successful treatment with clarithromycin for patients with polymyalgia rheumatica. | 2014 | Korean J. Intern. Med. | pmid:25045305 |
| Martin JH and Coombes I | Mortality from common drug interactions systems, knowledge and clinical reasoning to optimise prescribing. | 2014 | Intern Med J | pmid:25041768 |
| Bansal S and Chhibber S | Phytochemical-induced reduction of pulmonary inflammation during Klebsiella pneumoniae lung infection in mice. | 2014 | J Infect Dev Ctries | pmid:25022293 |
| Fouka E et al. | Low-dose clarithromycin therapy modulates Th17 response in non-cystic fibrosis bronchiectasis patients. | 2014 | Lung | pmid:25016929 |
| Lambert D et al. | Gastritis due to Helicobacter pylori, an unusual cause of chronic diarrhoea in HIV infected patients. | 2014 | Med Mal Infect | pmid:25015308 |
| Dalbøge CS et al. | Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis. | 2014 | J. Cyst. Fibros. | pmid:24035278 |
| Liu CP et al. | NO-releasing xanthine KMUP-1 bonded by simvastatin attenuates bleomycin-induced lung inflammation and delayed fibrosis. | 2014 | Pulm Pharmacol Ther | pmid:23518214 |
| Klesiewicz K et al. | PCR-RFLP detection of point mutations A2143G and A2142G in 23S rRNA gene conferring resistance to clarithromycin in Helicobacter pylori strains. | 2014 | Acta Biochim. Pol. | pmid:24927236 |
| Sugimoto M and Furuta T | Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. | 2014 | World J. Gastroenterol. | pmid:24914361 |
| Heo J and Jeon SW | Optimal treatment strategy for Helicobacter pylori: era of antibiotic resistance. | 2014 | World J. Gastroenterol. | pmid:24914324 |
| Glatz M and Muellegger RR | Drug-associated aquagenic wrinkling of the palms in an atopic male patient. | 2014 | BMJ Case Rep | pmid:24903725 |
| DiCicco M et al. | In vitro synergism of fosfomycin and clarithromycin antimicrobials against methicillin-resistant Staphylococcus pseudintermedius. | 2014 | BMC Microbiol. | pmid:24886369 |
| Noonan KA et al. | Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma. | 2014 | Cancer Immunol Res | pmid:24878583 |
| Gong EJ et al. | Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change? | 2014 | J. Korean Med. Sci. | pmid:24851029 |
| Jeon HK and Kim GH | Does standard triple therapy still have a role in first-line Helicobacter pylori eradication in Korea? | 2014 | J. Korean Med. Sci. | pmid:24851014 |
| Rasheed F et al. | Analysis of clinical isolates of Helicobacter pylori in Pakistan reveals high degrees of pathogenicity and high frequencies of antibiotic resistance. | 2014 | Helicobacter | pmid:24827414 |
| Wang Y et al. | Efficacy and safety of ecabet sodium as an adjuvant therapy for Helicobacter pylori eradication: a systematic review and meta-analysis. | 2014 | Helicobacter | pmid:24826809 |
| Graham DY et al. | Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. | 2014 | Clin. Gastroenterol. Hepatol. | pmid:23751282 |
| Onyekwere CA et al. | Rabeprazole, clarithromycin, and amoxicillin Helicobacter pylori eradication therapy: report of an efficacy study. | 2014 | World J. Gastroenterol. | pmid:24707145 |
| Wu JY et al. | Detection of genotypic clarithromycin-resistant Helicobacter pylori by string tests. | 2014 | World J. Gastroenterol. | pmid:24695835 |
| Sugimoto M et al. | Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion. | 2014 | Helicobacter | pmid:24690010 |
| Liu KY et al. | Efficacy and pharmacological mechanism of pronase-enhanced low-dose antibiotics for Helicobacter pylori eradication. | 2014 | Antimicrob. Agents Chemother. | pmid:24687504 |
| Ikawa K et al. | Pharmacokinetic modelling of serum and bronchial concentrations for clarithromycin and telithromycin, and site-specific pharmacodynamic simulation for their dosages. | 2014 | J Clin Pharm Ther | pmid:24661290 |
| Varvyanskaya A and Lopatin A | Efficacy of long-term low-dose macrolide therapy in preventing early recurrence of nasal polyps after endoscopic sinus surgery. | 2014 | Int Forum Allergy Rhinol | pmid:24659566 |
| Lee SH et al. | Detection and assessment of clarithromycin inducible resistant strains among Korean Mycobacterium abscessus clinical strains: PCR methods. | 2014 | J. Clin. Lab. Anal. | pmid:24652818 |
| Binh TT et al. | Discovery of novel mutations for clarithromycin resistance in Helicobacter pylori by using next-generation sequencing. | 2014 | J. Antimicrob. Chemother. | pmid:24648504 |
| Karaolia P et al. | Reduction of clarithromycin and sulfamethoxazole-resistant Enterococcus by pilot-scale solar-driven Fenton oxidation. | 2014 | Sci. Total Environ. | pmid:24012892 |
| Tursi A et al. | Decreasing efficacy of the standard seven-day triple therapy containing amoxycillin and clarithromycin in curing Helicobacter pylori infection in clinical setting in Italy: a 10-year follow-up study. | 2014 | Panminerva Med | pmid:24637473 |
| Wei Z et al. | Rome III criteria cannot distinguish patients with chronic gastritis from those functional dyspepsia patients. | 2014 | Helicobacter | pmid:24617669 |
| Rizzo A et al. | Antimicrobial effect of natural polyphenols with or without antibiotics on Chlamydia pneumoniae infection in vitro. | 2014 | Microb. Drug Resist. | pmid:23952319 |
| Wu JY et al. | Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate. | 2014 | Helicobacter | pmid:24612093 |
| Settin A et al. | Cure rate of Helicobacter pylori infection in Egyptian children related to CYP2C19 gene polymorphism. | 2014 | Indian J Gastroenterol | pmid:24610583 |
| Garza-González E et al. | A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication. | 2014 | World J. Gastroenterol. | pmid:24587620 |
| Okame M et al. | Complete regression of early-stage gastric diffuse large B-cell lymphoma in an HIV-1-infected patient following Helicobacter pylori eradication therapy. | 2014 | Clin. Infect. Dis. | pmid:24585569 |
| Mark TM et al. | Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma. | 2014 | Leuk. Lymphoma | pmid:24576165 |
| Zhang J et al. | Ocular penetration and pharmacokinetics of topical clarithromycin eye drops to rabbits. | 2014 | J Ocul Pharmacol Ther | pmid:24199739 |
| Takazono T et al. | Paradoxical response to disseminated non-tuberculosis mycobacteriosis treatment in a patient receiving tumor necrosis factor-α inhibitor: a case report. | 2014 | BMC Infect. Dis. | pmid:24576098 |